Trial Profile
A phase IIIB study evaluating the effect on serum lipids following a switch to atazanavir in HIV infected subjects evidencing virologic suppression on their first PI [protease inhibitor]-based antiretroviral therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary) ; HIV protease inhibitors
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 22 Dec 2005 New trial record.